Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.
Cellmid Ltd develops and sells diagnostic and therapeutic products for diseases such as cancer and chronic inflammatory conditions. The company's operating segment includes Diagnostics Cellmid/Lyramid Australia and Consumer Health which includes Advangen Australia; Advangen USA and Advangen Japan. It generates maximum revenue from the Consumer Health segment.
Sydney, NSW, 2000, Australia